'Metastatic colorectal cancer' presentation slideshows

Moderator Neil Love, MD

873 views • 73 slides

Background

Randomized Controlled Trials Examining Continuous Versus Intermittent Strategies Of Delivering Systemic Treatment For Untreated Metastatic Colorectal Cancer: A Meta-Analysis From The Cancer Care Ontario Program In Evidence-Based Care.

642 views • 49 slides

Background

Randomized Controlled Trials Examining Continuous Versus Intermittent Strategies Of Delivering Systemic Treatment For Untreated Metastatic Colorectal Cancer: A Meta-Analysis From The Cancer Care Ontario Program In Evidence-Based Care.

578 views • 49 slides

Management of Metastatic Colorectal Cancer: Focus on Targeted Therapy

Management of Metastatic Colorectal Cancer: Focus on Targeted Therapy. Management of Metastatic Colorectal Cancer: Focus on Targeted Therapy. Jimmy Hwang, MD Associate Professor, Hematology/Oncology John L. Marshall, MD Associate Professor, Hematology/Oncology Department of Medicine

2.2k views • 42 slides

Colorectal Discussion Beyond Progression: Is this progress?

Colorectal Discussion Beyond Progression: Is this progress?. Alan P. Venook, MD University of California, SF. Disclosures. Roche / Genentech, Regeneron and Sanofi have provided me with background information

518 views • 40 slides

525 views • 31 slides

ALM CAO

ALM CAO. AGITG. g. Peri-operative FOLFOX4 chemotherapy and surgery for resectable liver metastases from colorectal cancer Final efficacy results of the EORTC Intergroup phase III study 40983.

512 views • 30 slides

2007 A.S.C.O. Annual Meeting Chicago (USA), June 1-5

2007 A.S.C.O. Annual Meeting Chicago (USA), June 1-5. Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI vs FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer.

498 views • 30 slides

BICC-C Study

BICC-C Study. A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib versus Placebo as First-line Treatment for Patients with Metastatic Colorectal Cancer

532 views • 28 slides

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results of a randomized phase III trial. R. Hofheinz, F. Wenz, S. Post, A. Matzdorff, S. Laechelt, J. Hartmann,

375 views • 24 slides

IVD Validation and Regulation in Rx/Dx Combinations

IVD Validation and Regulation in Rx/Dx Combinations. FDA/Industry Statistics Workshop Classifiers in Combination Rx/Dx Submissions. Robert L. Becker, Jr, MD, PhD U.S. Food and Drug Administration Center for Devices and Radiological Health

335 views • 24 slides

ARCC Canadian Centre for Applied Research in Cancer Control

281 views • 19 slides

Infusional 5-FU/FA plus Oxaliplatin (FUFOX) vs. Capecitabine plus Oxaliplatin (CAPOX)

Tobias Arkenau. Infusional 5-FU/FA plus Oxaliplatin (FUFOX) vs. Capecitabine plus Oxaliplatin (CAPOX) as first-line treatment for metastatic colorectal cancer: safety and efficacy analysis from a phase III trial of the German AIO. Rationale for CAPOX in 1st-line ACRC.

301 views • 16 slides

ECCO ESMO 2011 GI Cancer Updates TAS102 and BSC vs. Placebo and BSC

ECCO ESMO 2011 GI Cancer Updates TAS102 and BSC vs. Placebo and BSC. Reviewer: Dr. Scott Berry Date posted: October 2011.

234 views • 10 slides

Reviewer: Dr Phil Bedard Date posted: June 21, 2007

Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): A Dutch Colorectal Cancer group (DCCG) phase III study Authors: Punt et al. Reviewer: Dr Phil Bedard Date posted: June 21, 2007. Background.

185 views • 8 slides

Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center POTENTIAL EARLY COLLABORATIONS

PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials. Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center POTENTIAL EARLY COLLABORATIONS May 24, 2010 National Cancer Institute. Industry/Commercial. Astra-Zeneca Merck

201 views • 4 slides

ABSTRACT (UPDATED)

TPS3634.

89 views • 1 slides

Introduction

K-RAS mutation status associated with clinical outcome in metastatic colorectal cancer patients treated with 5-fluorouracil/oxaliplatin

104 views • 1 slides

Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model .

# 460 Anti-angiogenic therapies for metastatic colorectal cancer (MCRC): Preliminary results of a systematic review and meta-analysis A. D. Wagner 1 , D. Arnold 2 , A. Grothey 3 , J. Haerting 4 , S. Unverzagt 1

163 views • 1 slides